Perrigo Financial Statements
NYSE: PRGOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Perrigo revenue and earnings
In fiscal 2025, Perrigo generated $4.25 billion in revenue, down 2.8% from fiscal 2024, its first annual decline since 2024. Perrigo reported a net loss of $1.43 billion, compared with a loss of $171.8 million a year earlier. Gross margin was 35.1% (down from 35.3%) and operating margin -26.4%.
Diluted earnings per share came in at -$10.29. Over the last 5 fiscal years, PRGO's revenue has grown at a 0.8% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Perrigo income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.25B | 4.37B | 4.66B | 4.45B | 4.14B | 4.09B | 3.87B | 4.73B | 4.95B | 5.28B |
| Revenue growth (YoY) | -2.75% | -6.06% | +4.58% | +7.56% | +1.24% | +5.64% | -18.21% | -4.34% | -6.33% | +24.92% |
| Cost of Revenue | 2.76B | 2.83B | 2.98B | 3.00B | 2.72B | 2.59B | 2.44B | 2.90B | 2.97B | 3.23B |
| Gross Profit | 1.49B | 1.54B | 1.68B | 1.46B | 1.42B | 1.49B | 1.43B | 1.83B | 1.98B | 2.05B |
| Operating Expenses | 2.62B | 1.43B | 1.53B | 1.38B | 1.01B | 1.23B | 1.26B | 1.59B | 1.38B | 4.05B |
| Research & Development | 95.40M | 112.20M | 122.50M | 123.10M | 122.00M | 121.70M | 119.20M | 218.60M | 167.70M | 184.00M |
| Selling, General & Admin | 962.40M | 1.01B | 1.16B | 1.10B | 1.02B | 1.02B | 1.02B | 1.03B | 1.06B | 1.12B |
| Operating Income | -1.12B | 112.90M | 151.90M | 78.90M | 410.40M | 265.20M | 174.70M | 236.50M | 598.20M | -2.00B |
| Other Income (Expense) | -13.20M | 900.00K | 10.40M | -53.10M | -26.70M | -16.30M | 68.90M | -6.10M | 10.10M | -22.70M |
| Pretax Income | -1.30B | -80.70M | -8.30M | -139.10M | 258.70M | -179.90M | -204.00M | 290.60M | 280.10M | -4.85B |
| Income Tax | 104.40M | 80.00M | -3.90M | -8.20M | 389.60M | -38.30M | -10.70M | 159.60M | 160.50M | -835.50M |
| Net Income | -1.43B | -171.80M | -12.70M | -140.60M | -68.90M | -162.60M | 146.10M | 131.00M | 119.60M | -4.01B |
| Net Income growth (YoY) | — | — | — | — | — | -211.29% | +11.53% | +9.53% | — | -3048.42% |
| EPS (Basic) | -10.29 | -1.25 | -0.09 | -1.04 | -0.52 | -1.20 | 1.07 | 0.95 | 0.84 | -28.01 |
| EPS (Diluted) | -10.29 | -1.25 | -0.09 | -1.04 | -0.52 | -1.19 | 1.07 | 0.95 | 0.84 | -28.01 |
| Shares Outstanding (Basic) | 138.50M | 137.40M | 135.30M | 134.50M | 133.60M | 136.10M | 136.00M | 137.80M | 142.30M | 143.30M |
| Shares Outstanding (Diluted) | 138.50M | 137.40M | 135.30M | 134.50M | 133.60M | 137.20M | 136.50M | 138.30M | 142.60M | 143.30M |
| EBITDA | -784.70M | 438.80M | 511.40M | 417.50M | 722.60M | 650.00M | 571.20M | 660.10M | 1.04B | -1.54B |
| Gross Margin | 35.14% | 35.27% | 36.09% | 32.69% | 34.22% | 36.57% | 37.05% | 38.71% | 40.02% | 38.86% |
| Operating Margin | -26.39% | 2.58% | 3.26% | 1.77% | 9.92% | 6.49% | 4.51% | 5.00% | 12.09% | -37.87% |
| Net Margin | -33.51% | -3.93% | -27.00% | -3.16% | -1.66% | -3.98% | 3.78% | 2.77% | 2.42% | -75.99% |
This table shows 10 annual periods of Perrigo's income statement, from FY 2025 back to FY 2016, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow PRGO's reporting calendar. What is a income statement?